Oruka Therapeutics (NASDAQ:ORKA) Announces Quarterly Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) announced its quarterly earnings data on Monday. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03), FiscalAI reports.

Oruka Therapeutics Stock Performance

ORKA stock traded up $1.70 during midday trading on Monday, reaching $104.56. 1,598,897 shares of the company’s stock traded hands, compared to its average volume of 1,078,571. The firm has a market capitalization of $6.92 billion, a PE ratio of -51.51 and a beta of -0.34. The company has a 50-day moving average price of $88.48 and a two-hundred day moving average price of $70.92. Oruka Therapeutics has a 52 week low of $25.23 and a 52 week high of $115.51.

Analyst Ratings Changes

A number of brokerages have recently commented on ORKA. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Guggenheim reaffirmed a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 26th. Finally, Wedbush reiterated an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $133.00.

Insider Transactions at Oruka Therapeutics

In other news, CEO Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the sale, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 179,950 shares of company stock valued at $16,492,680 over the last three months. Company insiders own 23.49% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.